http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2020163771-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ea0bc5dd9b6d576e553cee47214f6dcd http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d2145b5a4059d6b0aaf59e8e9b2210d9 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-44 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-574 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K19-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-64 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-44 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68 |
| filingDate | 2020-02-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c44ba80bf971c44ae1e9f57e7d4a8511 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7200f66af9b050e036752c5707f9d803 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_552b2946be2a89cc0123415018652e07 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c14d6184741c40a4d0403ae98e877c8e |
| publicationDate | 2020-08-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2020163771-A1 |
| titleOfInvention | Structure, manufacturing and uses of hoxd12-pde8a cell-penetrating peptides |
| abstract | Embodiments disclosed herein provide compositions for conjugates, including fusion proteins, and methods of using them to treat a variety of conditions, including cancer and/or autoimmune diseases. In some embodiments, the conjugates and/or fusion proteins incorporate a homeodomain (e.g., peptides derived from human HOX genes), to translocate functional and regulatory peptides and proteins or other biologically active molecules such as nucleic acids, which are not naturally associated with the human homeodomain, across cell and nuclear membranes to intended sites of action without provoking an unwanted immune response that may reduce exposure to the conjugate and/or result in a clinical adverse event. In further embodiments, disclosed conjugates and fusion proteins include a cAMP-degrading phosphodiesterase-8A (PDE8A) - C-Raf complex. In various embodiments, the disclosed compositions are suitable for delivery into a cell (i) the expression product of a gene of interest and/or (ii) novel peptides or polynucleotides to regulate gene function. |
| priorityDate | 2019-02-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 407.